Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01972919 · ClinicalTrials.gov registry record · Phase 2
MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer
A Phase 2 study of Unresectable Pancreatic Cancer, sponsored by Medical College of Wisconsin.
- Active
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT01972919: Active Phase 2 study of Unresectable Pancreatic Cancer, sponsored by Medical College of Wisconsin.
NCT01972919 is a Phase 2 study of Unresectable Pancreatic Cancer that is active but no longer recruiting, run by Medical College of Wisconsin. The registered enrollment target is 23 participants, below the 88-participant average among 4 other Unresectable Pancreatic Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01972919, a Phase 2 study of Unresectable Pancreatic Cancer, is active but no longer recruiting, sponsored by Medical College of Wisconsin.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is for people who have pancreas cancer for which surgery is not recommended. Potential patients must have already received several months of chemotherapy before they are eligible for this study and there will not have been any detectable spread of their tumor on imaging studies following this chemotherapy course.
Primary Outcome
This measure will be the number of subjects alive at one and two years following the end of radiation treatment, up to two years and seven weeks.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Concurrent chemotherapy (Gemcitabine, Capecitabine)
Study Locations (1)
Wisconsin
- Froedtert Hospital - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-12-10 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
What the registry record for NCT01972919 still lists
NCT01972919 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 88-participant average among 4 other Unresectable Pancreatic Cancer trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Unresectable Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT01972919 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01972919 about?
NCT01972919 is a clinical study titled "MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-Metastatic Pancreatic Cancer". This research study is for people who have pancreas cancer for which surgery is not recommended. Potential patients must have already received several months of chemotherapy before they are eligible for this study and there will not have been any detectable spread of their tumor on imaging studies f...
What is the current status of trial NCT01972919?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2015-12-10. Estimated completion is 2026-03.
What conditions does trial NCT01972919 study?
This clinical trial studies the following conditions: Unresectable Pancreatic Cancer.
What interventions are being tested in trial NCT01972919?
The interventions under investigation include: Radiation Therapy (RADIATION), Concurrent chemotherapy (Gemcitabine, Capecitabine) (DRUG).
Who is sponsoring clinical trial NCT01972919?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01972919 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
RECRUITING · Phase 1
-
Improving Informed Consent for Palliative Chemotherapy
COMPLETED · NA
-
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI